Areas where scientific evidence is lacking or incomplete.
All human clinical data originates from Russian-language publications and institutions. No Phase III randomised controlled trials conducted under ICH guidelines exist. Peer-reviewed replication outside of Russia remains sparse.
Implications: Without independent, large-scale validation, the existing efficacy data cannot meet Western regulatory standards. Results from small Russian trials (N=40-120) may not generalise across diverse populations.
Most clinical evidence is based on short-term studies of 14-28 days. There is a profound lack of longitudinal human safety data beyond 30 days, particularly regarding receptor desensitisation, immune system impacts, and GABAergic function.
Implications: Users engaging in cyclical use over years have no safety evidence to rely on. Theoretical risks of GABA receptor downregulation and BDNF exhaustion remain unresolved.
Interactions between Selank and common Western medications are largely unmapped, particularly SSRIs, SNRIs, antipsychotics, mood stabilisers, and other CNS depressants. The risk of serotonin syndrome has not been systematically evaluated.
Implications: Users combining Selank with psychiatric medications — the population most likely to seek anxiolytic peptides — have no evidence base for predicting interactions.
Many established studies have small sample sizes (N=40-120), lack rigorous placebo controls, or rely on open-label/single-blind designs rather than the gold-standard double-blind methodology.
Implications: Effect sizes reported in existing studies may be inflated by placebo response and observer bias. True therapeutic magnitude remains uncertain.
While nose-to-brain transport is proven in rodent models, the actual CNS concentration achieved via intranasal delivery in humans has not been measured with PET or SPECT imaging. Human nasal architecture may be significantly more restrictive.
Implications: The claimed mechanism of direct CNS access may be overstated. Benefits observed clinically could be from systemic absorption rather than nose-to-brain delivery, which would change the risk-benefit profile.
Selank binds to a non-benzodiazepine site on the GABA-A receptor that is insensitive to flumazenil, but the precise allosteric binding site and its full pharmacological profile have not been determined.
Implications: Without knowing the exact binding mechanism, predicting off-target effects or designing safer derivatives is limited. The mechanism distinction from benzodiazepines remains incompletely understood.
No dedicated research exists for pregnant or breastfeeding women, paediatric populations, or individuals with autoimmune disorders. The ADHD study in children is a single trial without replication.
Implications: These populations must be considered contraindicated by default, and the paediatric ADHD signal cannot be acted on until independently confirmed.
Expert disagreements and competing evidence.
Selank is not injected; insulin syringes should only be used as transfer tools to move the solution into nasal spray bottles
One research guide explicitly prohibits injection, positioning intranasal as the only acceptable route
Source: Specific peptide research protocol guide
Selank is usually given as a nasal spray or a tiny subcutaneous injection, with specific protocols for 0.5 mg doses administered five days per week
Multiple clinical and medical provider sources describe subcutaneous injection as a standard administration route with specific dosing schedules
Source: Clinical medical provider protocols and Russian clinical trials
Verdict Note
Intranasal is the preferred and safer route with the best-documented nose-to-brain delivery. Subcutaneous is clinically validated but carries higher immunogenicity risk per the FDA. The prohibition in one source likely reflects a risk-conservative research position rather than pharmacological impossibility.
Selank is remarkably devoid of the typical adverse effects of anxiolytics and has a benign side-effect profile with no immune suppression, allergic reactions, or mutagenic signals
Decades of Russian clinical use with formal safety testing showing no immune suppression, allergic reactions, embryotoxic, or mutagenic signals
Source: Russian regulatory data and clinical trial reports
The FDA placed Selank in Category 2 citing significant safety risks, primarily immunogenicity — a potentially life-threatening immune response
FDA Category 2 classification based on assessment of immunogenicity risk, particularly with compounded formulations
Source: FDA bulk drug substance assessment (2023)
Verdict Note
The Russian safety data was generated with pharmaceutical-grade material under controlled manufacturing. The FDA concern centres on compounded and research-grade products where purity, aggregation, and impurity profiles are uncontrolled. The safety claims are not contradictory — they apply to different product qualities.
The plasma half-life of the parent Selank peptide is 2 to 3 minutes
Majority of pharmacokinetic sources cite the 2-3 minute range
Source: Standard peptide pharmacokinetic literature
Selank was detected in its native form in rat blood plasma for 7-10 minutes, surpassing other oligopeptides with similar structures
One specific study detected intact Selank for up to 10 minutes in rat plasma
Source: Rat pharmacokinetic study
Verdict Note
The discrepancy may reflect different detection methods, assay sensitivity, or the distinction between intact parent peptide and active metabolic fragments. Both agree that Selank persists longer than its parent molecule tuftsin. The biological effects (hours to days) far outlast the plasma half-life regardless of which value is used.
Severe neurological disorders or seizure history is a contraindication for Selank use
One clinical source lists seizure history as a disqualifying condition
Source: Clinical provider contraindication list
Selank is studied for managing neuropsychiatric disorders and has potential in post-stroke recovery and traumatic brain injury rehabilitation
Multiple sources describe Selank's neuroprotective properties in brain injury and neuropsychiatric contexts
Source: Russian clinical trial data and neuroprotection research
Verdict Note
The contradiction reflects different risk tolerances. In supervised clinical settings with monitoring, Selank's neuroprotective properties may benefit neurological patients. In unsupervised self-administration, the seizure risk is real and unpredictable. The contraindication should be respected for self-use while remaining open for supervised clinical application.
Selank can be safely integrated with any psychoactive or neuroactive therapies and is safe for concurrent use with ethanol-containing products
One source makes a broad compatibility claim across psychoactive substances including ethanol
Source: Promotional clinical material
Selank is used to protect against and mitigate ethanol-induced memory impairment and gastric damage, suggesting it is a corrective treatment for alcohol's effects
Research demonstrates Selank's gastroprotective effects against ethanol-induced ulcers and its ability to rescue alcohol-impaired cognition
Source: Gastroprotection and cognitive rescue studies
Verdict Note
Selank may protect against alcohol's negative effects, but this does not mean concurrent use is 'safe' — it means the peptide can partially mitigate damage. The broad compatibility claim lacks nuance. Users should not interpret Selank as a licence to drink without consequences.